Jonathan A Fallowfield
Overview
Explore the profile of Jonathan A Fallowfield including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
2594
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sugimoto A, Saito Y, Wang G, Sun Q, Yin C, Lee K, et al.
Nature
. 2025 Mar;
PMID: 40074890
Hepatic stellate cells (HSCs) have a central pathogenetic role in the development of liver fibrosis. However, their fibrosis-independent and homeostatic functions remain poorly understood. Here we demonstrate that genetic depletion...
2.
Kasarinaite A, Ramos M, Beltran-Sierra M, Sutherland E, Rei P, Zhao M, et al.
Stem Cell Res Ther
. 2025 Mar;
16(1):130.
PMID: 40069876
The increase in metabolic dysfunction-associated steatotic liver disease (MASLD) and its progression to metabolic dysfunction-associated steatohepatitis (MASH) is a worldwide healthcare challenge. Heterogeneity between men and women in the prevalence...
3.
Brennan P, MacMillan M, Manship T, Moroni F, Glover A, Troland D, et al.
Nat Med
. 2025 Jan;
PMID: 39794616
Cirrhosis is a major cause of morbidity and mortality; however, there are no approved therapies except orthotopic liver transplantation. Preclinical studies showed that bone-marrow-derived macrophage injections reduce inflammation, resolve fibrosis...
4.
Perry A, Hadad N, Chatterjee E, Jimenez-Ramos M, Farber-Eger E, Roshani R, et al.
Cell Rep Med
. 2024 Dec;
5(12):101871.
PMID: 39657669
Hepatic steatosis is a central phenotype in multi-system metabolic dysfunction and is increasing in parallel with the obesity pandemic. We use a translational approach integrating clinical phenotyping and outcomes, circulating...
5.
Aberrant basement membrane production by HSCs in MASLD is attenuated by the bile acid analog INT-767
Ramachandran P, Brice M, Sutherland E, Hoy A, Papachristoforou E, Jia L, et al.
Hepatol Commun
. 2024 Nov;
8(12).
PMID: 39585303
Background: The farnesoid X receptor (FXR) is a leading therapeutic target for metabolic dysfunction-associated steatohepatitis (MASH)-related fibrosis. INT-767, a potent FXR agonist, has shown promise in preclinical models. We aimed...
6.
Innes H, Buch S, Kendall T, Fallowfield J, Guha I
Liver Int
. 2024 Oct;
44(12):3260-3273.
PMID: 39425533
Background And Aims: Individuals with genetic polymorphisms in UGT1A1 exhibit bilirubin levels that belie their risk of liver disease (Gilbert's syndrome) but it is not known if this phenomenon extends...
7.
Jacobs A, Morley S, Samuel K, Morgan K, Boswell L, Kendall T, et al.
World J Gastroenterol
. 2024 Aug;
30(31):3705-3716.
PMID: 39192998
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD), characterised by hepatic lipid accumulation, causes inflammation and oxidative stress accompanied by cell damage and fibrosis. Liver injury (LI) is also frequently reported...
8.
Kendall T, Chng E, Ren Y, Tai D, Ho G, Fallowfield J
Liver Int
. 2024 Aug;
44(10):2511-2516.
PMID: 39109545
Computational quantification reduces observer-related variability in histological assessment of metabolic dysfunction-associated steatotic liver disease (MASLD). We undertook stain-free imaging using the SteatoSITE resource to generate tools directly predictive of clinical...
9.
Drozdov I, Szubert B, Rowe I, Kendall T, Fallowfield J
Ann Hepatol
. 2024 Jul;
29(5):101528.
PMID: 38971372
Introduction And Objectives: Despite the huge clinical burden of MASLD, validated tools for early risk stratification are lacking, and heterogeneous disease expression and a highly variable rate of progression to...
10.
Fallowfield J, Ramos M
Expert Opin Emerg Drugs
. 2024 Apr;
29(3):187-192.
PMID: 38603460
No abstract available.